MDxHealth SA (O6C1)

Profile

https://mdxhealth.com

MDxHealth SA is a commercial-stage precision diagnostics company specializing in innovative molecular diagnostic solutions for urologic diseases, with a particular focus on prostate cancer detection and management. Its product portfolio features non-invasive tests such as Select mdx, a urine-based test for early prostate cancer risk assessment, and Confirm mdx, which analyzes previously biopsied tissue to further aid in the diagnosis of occult prostate cancer through epigenetic markers. MDxHealth also offers solutions addressing urinary tract infections and provides physicians with actionable genomic insights to support personalized treatment decisions. By leveraging proprietary genetic, epigenetic, and molecular technologies, the company aims to enhance the accuracy and efficiency of urologic disease diagnosis while supporting cost-effective care for healthcare systems. Founded in 2003 and headquartered in Herstal, Belgium, MDxHealth collaborates closely with international academic centers and medical organizations, underscoring its commitment to research-driven innovation in the healthcare sector and its significant role in advancing precision medicine within the diagnostics industry.